Sepsis

Resource Center

News
Research Summaries
Resources
FDA Alerts Pearls of Wisdom From the Journal
Insights
Commentary Podcasts Q&As Videos
Interactive
Polls Quizzes Slideshows
Events & Education

FDA Alerts

FDA Approval
FDA Phone screen
FDA Approval
Tecartus (brexucabtagene autoleucel) Receives FDA Approval for Relapsed or Refractory Mantle Cell Lymphoma
04/15/2026
Anthony Calabro, MA
The FDA has granted full approval for the use of brexucabtagene autoleucel in adults with relapsed or refractory mantle cell lymphoma, based on confirmatory ZUMA-2 data.
04/15/2026
FDA Approval
FDA Phone screen
FDA Approval
Tecartus (brexucabtagene autoleucel) Receives FDA Approval for Relapsed or Refractory Mantle Cell Lymphoma
04/15/2026
Anthony Calabro, MA
The FDA has granted full approval for the use of brexucabtagene autoleucel in adults with relapsed or refractory mantle cell lymphoma, based on confirmatory ZUMA-2 data.
04/15/2026
FDA Approval
FDA sign
FDA Approval
FDA Approves Orforglipron (Foundayo) for Chronic Weight Management
04/02/2026
Anthony Calabro, MA
The FDA approved oral GLP-1 orforglipron (Foundayo) for weight management without food or water restrictions.
04/02/2026
FDA Approval
FDA sign
FDA Approval
FDA Approves Orforglipron (Foundayo) for Chronic Weight Management
04/02/2026
Anthony Calabro, MA
The FDA approved oral GLP-1 orforglipron (Foundayo) for weight management without food or water restrictions.
04/02/2026
FDA Approval
FDA sign
FDA Approval
FDA Approves Orforglipron (Foundayo) for Chronic Weight Management
04/02/2026
Anthony Calabro, MA
The FDA approved oral GLP-1 orforglipron (Foundayo) for weight management without food or water restrictions.
04/02/2026
FDA Approval
FDA sign
FDA Approval
FDA Approves Orforglipron (Foundayo) for Chronic Weight Management
04/02/2026
Anthony Calabro, MA
The FDA approved oral GLP-1 orforglipron (Foundayo) for weight management without food or water restrictions.
04/02/2026
FDA Approval
FDA sign
FDA Approval
FDA Approves Orforglipron (Foundayo) for Chronic Weight Management
04/02/2026
Anthony Calabro, MA
The FDA approved oral GLP-1 orforglipron (Foundayo) for weight management without food or water restrictions.
04/02/2026
FDA Approval
FDA sign
FDA Approval
FDA Approves Orforglipron (Foundayo) for Chronic Weight Management
04/02/2026
Anthony Calabro, MA
The FDA approved oral GLP-1 orforglipron (Foundayo) for weight management without food or water restrictions.
04/02/2026
FDA Approval
FDA sign
FDA Approval
FDA Approves Orforglipron (Foundayo) for Chronic Weight Management
04/02/2026
Anthony Calabro, MA
The FDA approved oral GLP-1 orforglipron (Foundayo) for weight management without food or water restrictions.
04/02/2026
FDA Approval
phone that says FDA
FDA Approval
FDA Approves Awiqli (Insulin Icodec-Abae) as Once-Weekly Basal Insulin for Adults With Type 2 Diabetes
03/27/2026
Anthony Calabro, MA
The FDA has approved insulin icodec-abae as the first once-weekly basal insulin option for glycemic control in adults with type 2 diabetes.
03/27/2026